Cyclic AMP, protein kinase A, and phosphodiesterases: Proceedings of an international workshop

Hormone and Metabolic Research

Volumn 44, Issue 10, 2012, Pages 713-715

  Stratakis, C A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PHOSPHODIESTERASE;

CELL CYCLE REGULATION; CELL PROLIFERATION; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; CONGRESSES AS TOPIC; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HOMEOSTASIS; HUMANS; MICE; NEOPLASMS; PHOSPHORIC DIESTER HYDROLASES;

EID: 84865642131     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1301327     Document Type: Review

References (44)

1. Savai R, Pullamsetti S S, Banat G A, Weissmann N, Ghofrani H A, Grimminger F, Schermuly R T. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs: 2010; 19 117 131
2. Makhlouf A, Kshirsagar A, Niederberger C. Phosphodiesterase 11: a brief review of structure, expression and function. Int J Impot Res: 2006; 18 501 509
3. Taskén K, Skålhegg B S, Taskén K A, Solberg R, Knutsen H K, Levy F O, Sandberg M, Orstavik S, Larsen T, Johansen A K, Vang T, Schrader H P, Reinton N T, Torgersen K M, Hansson V, Jahnsen T. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res: 1997; 31 191 204
4. Kim C, Xuong N H, Taylor S S. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science: 2005; 307 5710 690 696
5. Kim C, Cheng C Y, Saldanha S A, Taylor S S. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell: 2007; 130 1032 1043
6. Francis S H, Corbin J D. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci: 1999; 36 275 328
7. Kim M J, Lee J H, Park S Y, Hong K W, Kim C D, Kim K Y, Lee W S. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation. Pharmacol Res: 2006; 54 261 267
8. Zhang L, Murray F, Zahno A, Kanter J R, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps T J, Insel P A. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA: 2008; 105 19532 19537
9. Sengupta R, Sun T, Warrington N M, Rubin J B. Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci: 2011; 32 337 344
10. Jeon Y H, Heo Y S, Kim C M, Hyun Y L, Lee T G, Ro S, Cho J M. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci: 2005; 62 1198 1220
11. Bender A T, Beavo J A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev: 2006; 58 488 520
12. Weinstein L S, Shenker A, Gejman P V, Merino M J, Friedman E, Spiegel A M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med: 1991; 325 1688 1695
13. Kirschner L S, Carney J A, Pack S D, Taymans S E, Giatzakis C, Cho Y S, Cho-Chung Y S, Stratakis C A. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet: 2000; 26 89 92
14. Carney J A, Gordon H, Carpenter P C, Shenoy B V, Go V L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore): 1985; 64 270 283
15. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libé R, Rene-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner L S, Bertagna X, Carney J A, Stratakis C A. Mutations in regulatory subunit type 1 A of cyclic adenosine 5-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab: 2009; 94 2085 2091
16. Greene E L, Horvath A D, Nesterova M, Giatzakis C, Bossis I, Stratakis C A. In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay. Hum Mutat: 2008; 29 633 639
17. Groussin L, Kirschner L S, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney J A, Luton J P, Bertagna X, Stratakis C A, Bertherat J. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1 A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet: 2002; 71 1433 1442
18. Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libé R, Remmers E, Rene-Corail F, Faucz F R, Clauser E, Calender A, Bertagna X, Carney J A, Stratakis C A. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum Mutat: 2010; 31 369 379
19. Rothenbuhler A, Stratakis C A. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab: 2010; 24 389 399
20. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner L S, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis C A. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res: 2003; 63 5308 5319
21. Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin K J, Stein E, Levine E, Delimpasi G, Hsiao H P, Keil M, Heyerdhal S, Matyakhina L, Libé R, Fratticci A, Kirschner L S, Craner K, Gaillard R C, Bertagna X, Carney J A, Bertherat J, Bossis I, Stratakis C A. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet: 2006; 38 794 800
22. Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, Stein E, Kamvissi V, Soni P, Bossis I, De Herder W, Carney J A, Bertherat J, Gregersen P K, Remmers E F, Stratakis C A. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res: 2006; 66 11571 11575
23. Libé R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F, Groussin L, Bertagna X, Raffin-Sanson M L, Stratakis C A, Bertherat J. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res: 2008; 14 4016 4024
24. Libé R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin-Sanson M L, Siegel J, Moran J, Drori-Herishanu L, Faucz F R, Lodish M, Nesterova M, Bertagna X, Bertherat J, Stratakis C A. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab: 2011; 96 E208 E214
25. Faucz F R, Horvath A, Rothenbuhler A, Almeida M Q, Libé R, Raffin-Sanson M L, Bertherat J, Carraro D M, Soares F A, GdeC Molina, Canpos A H, Alexandre R B, Bendhak M L, Nesterova M, Stratakis C A. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J Clin Endocrinol Metab: 2011; 96 E135 E140
26. Horvath A, Giatzakis C, Tsang K, Greene E, Osorio P, Boikos S, Libé R, Patronas Y, Robinson-White A, Remmers E, Bertherat J, Nestrova M, Stratakis C A. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet: 2008; 16 1245 1253
27. Tsai L C, Shimizu-Albergine M, Beavo J A. The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol: 2011; 79 639 648
28. Horvath A, Mericq V, Stratakis C A. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N Engl J Med: 2008; 358 750 752
29. Rothenbuhler A, Horvath A, Faucz F, Almeida M, Lodish M, Libé R, Nesterova M, Bertherat J, Stratakis C A. Three novel mutations in PDE8B, a cAMP phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumors. Program of the 91st Annual Meeting of the Endocrine Society, Washington, DC: 2009
30. Bimpaki E I, Nesterova M, Stratakis C A. Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes. Eur J Endocrinol: 2009; 161 153 161
31. Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y, Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3,5-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun: 1998; 250 751 756
32. Arnaud-Lopez L, Usala G, Ceresini G, Mitchell B D, Pilia M G, Piras M G, Sestu N, Maschio A, Busonero F, Albai G, Dei M, Lai S, Mulas A, Crisponi L, Tanaka T, Bandinelli S, Guralnik J M, Loi A, Balaci L, Sole G, Prinzis A, Mariotti S, Shuldiner A R, Cao A, Schlessinger D, Uda M, Abecasis G R, Nagaraja R, Sanna S, Naitza S. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet: 2008; 82 1270 1280
33. Volpato C B, De Grandi A, Gögele M, Taliun D, Fuchsberger C, Facheris M F, Minelli C, Pattaro C, Pramstaller P P, Hicks A A. Linkage and association analysis of hyperthyrotropinaemia in an Alpine population reveal two novel loci on chromosomes 3q28-29 and 6q26-27. J Med Genet: 2011; 48 549 556
34. Lania A, Persani L, Ballaré E, Mantovani S, Losa M, Spada A. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab: 1998; 83 1624 1628
35. Knight W E, Yan C. Cardiac cyclic nucleotide phosphodiesterase: function, regulation, and therapeutic prospects. Horm Metab Res: 2012; 44 766 775
36. Mantovani G, Elli F M, Spada A. GNAS epigenetic defects and pseudohypoparathyroidism: time for a new classification? Horm Metab Res: 2012; 44 716 723
37. Zhang S, Kaplan F S, Shore E M. Different roles of GNAS and cAMP signaling during early and late stages of osteogenic differentiation. Horm Metab Res: 2012; 44 724 731
38. Silve C, Clauser E, Linglart A. Acrodysostosis. Horm Metab Res: 2012; 44 749 758
39. Yu B, Ragazzon B, Rizk-Rabin M, Bertherat J. Protein kinase A alterations in endocrine tumors. Horm Metab Res: 2012; 44 741 748
40. Tsai L C, Beavo J A. Regulation of adrenal steroidogenesis by the high-affinity phosphodiesterase 8 family. Horm Metab Res: 2012; 44 790 794
41. Bastepe M. Relative functions of Gαs and its extra-large variant XLαs in the endocrine system. Horm Metab Res: 2012; 44 732 740
42. Ahmad F, Degerman E, Manganiello V C. Cyclic nucleotide phosphodiesterase 3 signaling complexes. Horm Metab Res: 2012; 44 776 785
43. Hussain M A, Stratakis C A, Kirschner L. Prkar1a in the regulation of insulin secretion. Horm Metab Res: 2012; 44 759 765
44. Vincent P, Castro L R, Gervasi N, Guiot E, Brito M, Paupardin-Tritsch D. PDE4 control on cAMP/PKA compartmentation revealed by biosensor imaging in neurons. Horm Metab Res: 2012; 44 786 789